Pacylex News has migrated to Newsroom. Click the link below to access the latest articles and press releases.
Pacylex is excited to announce the publication in the journal Current Oncology of data from the first patient. The paper entitled “Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-cell Lymphoma” describes how an eighty-six year old woman with relapsed diffuse large B-cell lymphoma (DLBCL) received oral PCLX-001, a small molecule, N-myristoyltransferase (NMT) inhibitor, as the initial patient in a phase 1 dose escalation clinical trial.